Navigation Links
Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
Date:5/2/2013

SAN DIEGO, May 02, 2013 /PRNewswire/ -- Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz , MBChB, D.Phil., President and CEO of Abide Therapeutics.  "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases." 

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products. Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry , Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories. "We look forward to working with Abide on the discovery and development of important new medicines."

About Serine Hydrolases

The large family of serine hydrolases are validated but largely under explored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases.  The technology provides a rapid and effective method for target identification and validation.  

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger , that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas.  Abide is located in San Diego.  To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
2. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
3. SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board
4. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
5. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
6. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
9. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
10. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
11. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):